During the meeting, the Health Industry Expo was also held simultaneously. As a national team in the field of medical science and technology innovation, CAMS&PUMC demonstrated a lot of landmark achievements concerning new drug discovery, vaccine R&D, development of medicinal plant resources, and medical device R&D in the “favorable and innovative” exhibition area. Cui Li, Vice Minister of the NHFPC, Qin Huaijin, Director, Division of Science and Education of the NHFPC, Director-General Tedros Adhanom Ghebreyesus, Executive Director Michel Sidibé, and ministerial-level officers from other countries visited the exhibition area of CAMS&PUMC. President Cao accompanied them to visit the exhibition. Bicyclol, developed by the Institute of Materia Medica CAMS/PUMC, came into the market in Russia and other seven countries along the “Belt and Road”. Bifendate has been sold to South Korea, Egypt, Vietnam, Burma and other countries. Enterovirus 71 vaccine independently developed by the Institute of Pathogen Biology of CAMS/PUMC was the first to appear on the international market. Sabin inactivated polio virus vaccine was made available on the market to fill the blank in China.The whole-tree agrawood-inducing technique, independently developed by the Institute of Medicinal Plant is the world’s first one to produce high-quality Aquilariae Resinatum Lignum in a stable and efficient manner and has been used as the pilot product in the eight countries along the “Belt and Road”. The comprehensive utilization of Panax notoginseng has yielded economic and social benefits in a wide range of aspects. The ophthalmic ultrasonic diagnosis and treatment equipment independently designed by the Institute of Biomedical Engineering, has been exported to more than 60 countries and regions, enjoying the great popularity of countries along the “Belt and Road”.